63746-25-8

Usage

Uses

Used in Chemical Industry:
2-Amino-5-methoxycarbonyl Benzoic Acid is used as a chemical intermediate for the synthesis of various products. Its reactivity allows it to be incorporated into the production of plastics, resins, and other chemical compounds.
Used in Pharmaceutical Industry:
2-Amino-5-methoxycarbonyl Benzoic Acid is used as a building block in the development of pharmaceuticals. Its unique structure and reactivity make it a valuable component in the creation of new drugs and medications.
Used in Research and Development:
2-Amino-5-methoxycarbonyl Benzoic Acid is utilized in research settings to study its properties and potential applications. Scientists and researchers explore its reactivity and interactions with other compounds to discover new uses and improve existing processes.
Note: Since the provided materials do not contain specific applications or industries for 2-Amino-5-methoxycarbonyl Benzoic Acid, the uses listed above are general and based on the information available about its chemical properties and potential applications in the benzoic acid family. It is recommended to handle 2-AMINO-5-METHOXYCARBONYL BENZOIC ACID with caution until more comprehensive information is made available.

Upstream product

• 67-56-1 methanol 
• 33890-03-8 4-aminoisophthalic acid 
• 63746-12-3 dimethyl 4-aminoisophthalate 
• 7501-68-0 4-acetamidoisophthalic acid 
• 4315-09-7 4-nitroisophthalic acid 
• 89-87-2 2,4-dimethylnitrobenzene 
• 2050-43-3 N-(2,4-dimethylphenyl)acetamide 
• 95-68-1 2,4-Xylidine 
• 201230-82-2 carbon monoxide 
• 5326-47-6 2-amino-5-iodobenzoic acid 
• 159847-80-0 4-amino-3-cyanobenzoic acid methyl ester 
• 76143-33-4 5-(methoxycarbonyl)-2-nitrobenzoic acid 

Downstream Products

• 85742-72-9 3-benzylidene-1,2,3,9-tetrahydro-9-oxopyrrolo<2,1-b>quinazoline-7-carboxylic acid, methyl ester 
• 85743-38-0 3-(3'-methylbenzylidene)-1,2,3,9-tetrahydro-9-oxopyrrolo<2,1-b>quinazoline-7-carboxylic acid, methyl ester 
• 85743-39-1 3-(4'-methylbenzylidene)-1,2,3,9-tetrahydro-9-oxopyrrolo<2,1-b>quinazoline-7-carboxylic acid, methyl ester 
• 85743-33-5 3-(4'-fluorobenzylidene)-1,2,3,9-tetrahydro-9-oxopyrrolo<2,1-b>quinazoline-7-carboxylic acid, methyl ester 
• 85743-30-2 3-(2'-methylbenzylidene)-1,2,3,9-tetrahydro-9-oxopyrrolo<2,1-b>quinazoline-7-carboxylic acid, methyl ester 
• 117145-66-1 2-(4-tert-Butylphenyl)-6-methoxycarbonyl-4H-3,1-benzoxazin-4-one 
• 1374778-43-4 4-(3-chlorobenzo[b]thiophene-2-carboxamido)-3-(5-methylthiazol-2-ylcarbamoyl)benzoic acid 
• 1374779-84-6 C₁₃H₁₃N₃O₃S 
• 1374779-86-8 C₂₂H₁₆ClN₃O₄S₂ 

Relevant academic research and scientific papers

Pyrazolone-quinazolone hybrids: A novel class of human 4-hydroxyphenylpyruvate dioxygenase inhibitors

4-Hydroxyphenylpyruvate dioxygenase (HPPD), converting 4-hydroxyphenylpyruvate acid to homogentisate, is an important target for treating type I tyrosinemia and alkaptonuria due to its significant role in tyrosine catabolism. However, only one commercial drug, NTBC, also known as nitisinone, has been available for clinical use so far. Herein, we have elucidated the structure-based design of a series of pyrazolone-quinazolone hybrids that are novel potent human HPPD inhibitors through the successful integration of various techniques including computational simulations, organic synthesis, and biochemical characterization. Most of the new compounds displayed potent inhibitory activity against the recombinant human HPPD in nanomolar range. Compounds 3h and 3u were identified as the most potent candidates with Kivalues of around 10 nM against human HPPD, about three-fold more potent than NTBC. Molecular modeling indicated that the interaction between the pyrazolone ring and ferrous ion, and the hydrophobic interaction of quinazolone with its surrounding residues, such as Phe347 and Phe364, contributed greatly to the high potency of these inhibitors. Therefore, compounds 3h and 3u could be potentially useful for the treatment of type I tyrosinemia and other diseases with defects in tyrosine degradation.

NEUROTRYPSIN INHIBITORS

The invention relates to acylamino-phthalic acid amides and related compounds of formula (I) wherein A is -CONR3R4,-NR5COR6, -NHR7, -OR8, -mR9, -CH2NRI0R11, -(CH2)2-R12, -CH=CH-R12, -C=C-R12, optionally substituted phenyl, optionally substituted thiophenyl, or optionally substituted 1,2,3-triazol-4-yl, W is hydrogen, hydroxy or carboxymethoxy, Y is carboxy, methoxycarbonyl or 2H-tetrazol-5-yl, and the various substituents R have the meanings indicated in the description. These compounds are useful for the treatment and/or prophylaxis of skeletal muscle atrophy, schizophrenia and Alzheimer?s disease, and as cognitive enhancers.

The use of biocatalysis in the synthesis of labelled compounds

Since most biotransformations are highly chemo-, regio- and stereoselective, they offer many opportunities for the synthesis of compounds that are not easily attainable by classical organic chemistry, The catalytic properties of the cytochrome P450 (CYP45

PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM

The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides compounds represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C1-C6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.

Substituted pyrrolo[2,1-b]quinazolines and pyrido[2,1-b]quinazolines useful for the treatment of or the prevention of gastrointestinal ulcers

Substituted Pyrrolo [2,1-b] and Pyrido [2, 1 b] Quinazolines are provided, together with pharmaceutical compositions, containing them. The compounds have pharmaceutical utility, and are particularly useful for the treatment of or prevention of the formati

2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation

3,4-Dihydro-4-oxo-quinazoline derivatives substituted in the 2-position by a substituted phenyl group are disclosed. The derivatives possess anti-allergy properties and can be used for the treatment of allergic conditions.